Table 1.
Author/Year | Stage/Histology/Grade | Site of skin metastasis | Chemotherapy regime | Cycles | Best response |
---|---|---|---|---|---|
This report/2019 | IB1/SCC/Differentiated | Thigh and vulva | PTX-CDDP-BV | 6 | CR |
Özcan et al. [19]/2017 | IB2/SCC/N/A | Vulva | 1st line; PTX-CBDCA | 2 | PD |
2nd line; GEM-BV | N/A | PD | |||
IB1/SCC/N/A | Umbilicus (incisional scar), abdominal wall | 1st line; PTX-CBDCA | 1 | N/A | |
2nd line; GEM-BV + RT | 1 | N/A | |||
Benoulaid et al. [20]/2016 | IIIB/SCC/Moderately differentiated | Abdominal wall | CBDCA | 4 | PD |
Basu and Mukherjee [21]/2013 | IIA/SCC/Moderately differentiated | Thigh, inguinal region | CDDP-PTX + palliative RT | 6 | PR |
Behtash et al. [16]/2008 | IIB/SCC/N/A | Umbilicus | PTX-CBDCA | 6 | PR |
Behtash et al. [22]/2002 | IIA/SCC/N/A | Abdominal wall (drain site) | Cisplatin-5FU + palliative RT | 6 | PR |
Palaia et al. [23]/2002 | IIB/SCC/Poorly differentiated | Abdominal wall | Palliative chemotherapy (PTX) | 10 | CR |
Kagen et al. [24]/2001 | IB/SCC/Poorly differentiated | Thigh | Ifosfamide | N/A | PD |
Freeman et al. [25]/1982 | IVB/SCC/N/A | Abdominal wall | RT + Bleomycin-MTX -cyclophosphamide | N/A | CR |
5FU 5 fluorouracil, BV bevacizumab, CBDCA carboplatin, CDDP cisplatin, CR complete response, GEM gemcitabine, MTX methotrexate, N/A not assessed, PD progressive disease, PR partial response, PTX paclitaxel, RT radiotherapy, SCC squamous cell carcinoma